V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population. V116 is specifically designed t...
Merck Announced V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials (Read Announcement) Other Pipeline Updates FDA Approved New Indication for Merck’s PREVYMIS for Prevention of Cytom...
V116. This vaccine will provide protection and coverage for adults of 85% of the serotypes that impact adults with pneumococcal disease; much better than any other product out there today or any other product that is in development today. So, we believe this will be a significant advancement...
FDA Granted Priority Review to Merck’s New BLA for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Based on Results From Multiple Phase 3 Trials; FDA Set PDUFA Date of June 17, 2024 (Read Announcement) Merck’s V116, an Investigat...
Regarding our COVID-19 research programs, Merck has made the decision to discontinue development of its vaccine candidate V590 and V591. This decision was based on clinical findings from Phase 1 study showing that while the vaccines were well tolerated, immune responses were inferior to those obs...
Thank you. If I could ask you a question on V940, the cancer vaccine, what tumor types outside of melanoma, do you already have any positive human data and even if those are earlier stage? And if you don’t have any human data in non-melanoma tumor types, can you talk about animal...
(n=8,830) investigating the safety, tolerability and immunogenicity of V116 in various adult populations. These include adults with and without chronic medical conditions associated with an increased risk of pneumococcal...
CAPVAXIVE (V116) is specifically designed for adults and covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults 50 years of age and older Across four Phase 3 studies, CAPVAXIVE demonstrated robust imm...